Can a safer blood thinner protect kidney patients from deadly clots?
NCT ID NCT07404436
First seen Feb 15, 2026 · Last updated May 07, 2026 · Updated 12 times
Summary
This study compares two blood thinners—rivaroxaban and warfarin—in people with a kidney condition called idiopathic membranous nephropathy who are at high risk for dangerous blood clots. About 134 participants will take one of the medications for 6 months to see which better prevents clots like deep vein thrombosis and pulmonary embolism. The goal is to find a safer, more effective way to manage clot risk in these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friedship Hospital
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.